Abstract:Background Cardiac amyloidosis (CA) is associated with a high mortality rate due to sudden or progressive heart failure. It is often misdiagnosed due to non-specific symptoms, and its true incidence and prevalence in the United Kingdom (UK) remain uncertain. Purpose To describe patient characteristics and incidence of CA in the UK clinical setting using electronic health records. Methods In this retrospective observational study, anonymised, linked primary and secondary care data (Clinical Practice Research Datalink, CPRD and Hospital Episode Statistics, HES) were used to describe individuals diagnosed with CA. The CPRD database contains de-identified patient data sourced from a sample of general practitioner (GP) practices in the UK. Patients aged 18 years and older with a recorded Read or SNOMED-CT diagnosis code for CA or record of treatment with tafamidis (a licensed but not reimbursed treatment for transthyretin amyloid cardiomyopathy, ATTR-CM in the UK) in the period between January 2004 to December 2021 were included. The index date was defined as the earliest recorded date of CA diagnosis or tafamidis treatment. Demographic and clinical data were summarised using descriptive statistics. Incidence rates were reported per 100,000 person-years (PY). Results There were a total of 3,788 patients with CA (mean age: 67 years; 61% males) of which only 277 were coded as having wild-type transthyretin (ATTRwt) CA in mostly older patients (mean age: 79 years). The low patient counts of ATTRwt amyloidosis could be attributed to the lack of specificity in CA types and the low utilisation of ATTR amyloidosis codes. Heart Failure, essential hypertension and dyspnoea were the most common clinical presentations recorded in the 12 months to first diagnosis code or tafamidis prescription for CA (Table). The incidence of CA varied from 0.75 in 2004 to a peak of 1.96 in 2021, per 100,000 PY; a 2.9-fold increase in newly coded diagnoses in CA. There was a slight decline in the rates in 2020 and 2021 (Figure). Incidence rates in males and females increased over the 17-year period, with males consistently having higher rates than females. The incidence rate in females started from a lower base at 0.62/100,000 PY in 2004, increased by a factor of 1.9 to 1.1/100,000 PY, whereas in males it started at 0.88/100,000 PY and rose by a factor of 2.9 to 2.5 /100,000 PY. Incidence rates in subgroup populations have also been analysed. Conclusions In the UK clinical setting, the incidence rate of newly coded CA increased overall between 2004 and 2021, as well as in both male and female subgroups. The data suggest CA is becoming more common, or that awareness has improved, and there is now an urgent need for enhanced methods of detection, characterisation, and the need for thorough data capture to shape future pathway advancements.

Race And Socioeconomic Status Impact Diagnosis And Clinical Outcomes In Transthyretin Cardiac Amyloidosis

Racial And Ethnic Disparities In In-hospital Outcome Of Wild Type Transthyretin Cardiac Amyloidosis: A Nationwide Inpatient Analysis

Race, Genotype, and Prognosis in Black Patients with Transthyretin Cardiac Amyloidosis

Assessing Screening For Transthyretin Cardiac Amyloidosis Among Patients At A Safety Net Hospital In Metro Atlanta

Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US

The Impact of Active Ascertainment on Gender-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study

Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis

Non-Cardiac Amyloidosis Findings Are Not Increased in African American Carriers of TTR V142I with Heart Failure and/or Arrhythmia

Temporal Outcomes of Patients Diagnosed With Transthyretin Cardiac Amyloidosis

Cardiovascular Burden of the V142I Transthyretin Variant

Validation Of The Transthyretin Amyloidosis Cardiomyopathy Score In A Black And Hispanic Screening Population: An Interim Analysis Of The First 342 Cases From The Scan-mp Study

Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction

Healthcare Resource Utilization And Disease Burden In Patients With Transthyretin Amyloidosis With Cardiomyopathy: Results From The Amyloidosis Research Consortium Transthyretin Amyloidosis Burden Of Illness Study

Racial Disparities In Outpatient Medical Management Of Patients With Heart Failure With Reduced Ejection Fraction

Patient characteristics and incidence of cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Changes in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction

Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis

Racial differences in takotsubo cardiomyopathy outcomes in a large nationwide sample

Prognostic implications of negative dobutamine stress echocardiography in African Americans compared to Caucasians

Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis